Skip to main contentSkip to navigationSkip to search

Press release

Camurus to present at Jefferies 2023 Healthcare Conference London

01 November 2023

Lund, Sweden — 1 November 2023 — Camurus (Nasdaq Stockholm; CAMX), a commercial-stage pharmaceutical company developing innovative medications for severe and chronic diseases, today announced that Fredrik Tiberg, President and Chief Executive Officer, will participate in a fireside chat about the company’s business progress and R&D pipeline developments at Jefferies 2023 Healthcare Conference in London on 15 November at 8:30-8:55 am local time (GMT).

A live webcast of the presentation can be accessed via:

For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37

About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit

This information was submitted for publication at 8:00 am CET on 1 November 2023.

TypeError: Cannot read properties of undefined (reading 'url')